<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278341</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0613</org_study_id>
    <secondary_id>2013-001497-16</secondary_id>
    <nct_id>NCT02278341</nct_id>
  </id_info>
  <brief_title>Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis</brief_title>
  <acronym>Pyrenees</acronym>
  <official_title>A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to explore a new therapy for anemia in patients with end stage renal
      disease (ESRD) on dialysis. Anemia is a reduced number of red blood cells or hemoglobin.
      Hemoglobin (which contains iron) is important for the transport of oxygen in your blood. The
      purpose of this study is to evaluate if roxadustat is effective and safe in the maintenance
      treatment of anemia in ESRD patients on stable dialysis. Roxadustat will be compared to
      epoetin alfa and darbepoetin alfa, commercially available medicines for treatment of anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consist of three study periods as follows:

        -  Screening Period: up to 6 weeks

        -  Treatment Period: a minimum of 52 weeks up to a maximum of 104 weeks

        -  Follow-up Period: 4 weeks
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 21, 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EU (European Medicines Agency): Hemoglobin (Hb) change from baseline to the average Hb of weeks 28 to 36 without having received rescue therapy</measure>
    <time_frame>Baseline and Weeks 28 to 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>US (Food and Drug Administration): Hemoglobin (Hb) change from baseline to the average Hb of weeks 28 to 52, regardless of rescue therapy</measure>
    <time_frame>Baseline and Weeks 28 to 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hb response without having received rescue therapy within 6 weeks prior to and during this 8-week evaluation period</measure>
    <time_frame>Weeks 28 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Low Density Lipoprotein (LDL) cholesterol to the average LDL cholesterol</measure>
    <time_frame>Baseline and Weeks 12 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean monthly intravenous (IV) iron use (mg)</measure>
    <time_frame>Day 1 to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure effect: Change from baseline in mean arterial pressure (MAP) to the average MAP value</measure>
    <time_frame>Baseline and Weeks 20 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure effect: Time to an increase in blood pressure</measure>
    <time_frame>Weeks 1 to 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SF-36 Physical Functioning (PF) sub-score to the average PF sub-score</measure>
    <time_frame>Baseline and Weeks 12 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SF-36 Vitality (VT) sub-score to the average VT sub-score</measure>
    <time_frame>Baseline and Weeks 12 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb response during weeks 28 and 36 regardless of use of rescue therapy</measure>
    <time_frame>Up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb change from baseline to each postdosing time point</measure>
    <time_frame>Baseline up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb level averaged over weeks 28 to 36, 44 to 52, and 96 to 104 without use of rescue therapy within 6 weeks prior to and during these 8-week evaluation periods</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb change from baseline to the average Hb value of weeks 28 to 36, 44 to 52, and 96 to 104 regardless of the use of rescue therapy</measure>
    <time_frame>Baseline and up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Hb values within 10.0 to 12.0 g/dL in weeks 28 to 36, 44 to 52, and 96 to 104 without use of rescue therapy within 6 weeks prior to and during these 8-week evaluation periods</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hospitalization</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalization</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants having received rescue therapy</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants having received Red Blood Cell (RBC) transfusions</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RBC packs per subject</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of RBC transfused per subject</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants having received IV iron supplementation</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean monthly IV iron (mg) per subject during weeks 37-52 and weeks 53-104</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants having required oral iron supplementation</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean monthly oral iron (mg) use per subject during day 1 to week 36, weeks 37 to 52, and weeks 53-104</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to each postdosing study visit in Total cholesterol</measure>
    <time_frame>Baseline up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to each postdosing study visit in LDL/High-density Lipoprotein (HDL) ratio</measure>
    <time_frame>Baseline up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to each postdosing study visit in Non-HDL cholesterol</measure>
    <time_frame>Baseline up to End of Study (EOS) (Up to week 108</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to each postdosing study visit in Apolipoproteins A1 and B</measure>
    <time_frame>Baseline up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to each postdosing study visit in ApoB/ApoA1 ratio</measure>
    <time_frame>Baseline up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of mean LDL cholesterol &lt;100 mg/dL calculated over weeks 12 to 28</measure>
    <time_frame>Up to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of achieved antihypertensive treatment goal in Chronic Kidney Disease (CKD) subjects (Systolic Blood Pressure (SBP) &lt; 140 mmHg and Diastolic Blood Pressure (DBP) &lt; 90 mmHg)based on the mean SBP and mean DBP calculated over weeks 12 to 28</measure>
    <time_frame>Up to week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to the average value of weeks 12 to 28 in Short Form 36 (SF-36) Physical Component Score</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to the average value of weeks 12 to 28 in Anemia Subscale (&quot;Additional Concerns&quot;) of Functional Assessment of Cancer Therapy-Anemia (FACT-An) Score</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to the average value of weeks 12 to 28 in Total FACT-An Score</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to the average value of weeks 12 to 28 in European Quality of Life 5 Domain 5 Level (EQ-5D 5L) visual analogue scale (VAS) Score</measure>
    <time_frame>Baseline and weeks 12 to 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' Global Impression of Change (PGIC)</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to each study visit in Serum hepcidin</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to each study visit in Serum ferritin</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to each study visit in Transferrin Saturation (TSAT)</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to each study visit in Glycated hemoglobin (HbA1c) level</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by occurrence of Adverse Events (AEs)</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by occurrence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by occurrence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by occurrence of Treatment Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with vital signs abnormalities and/or adverse events</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by 12- lead electrocardiogram (ECG)</measure>
    <time_frame>Up to End of Treatment (EOT) (Up to week 104)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant laboratory value abnormalities and/or adverse events</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by occurrence of prespecified adjudicated cardiovascular events</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
    <description>Major cardiovascular adverse events: myocardial infarction, death from all causes, chronic heart failure requiring hospitalization, unstable angina requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by time to occurrence of prespecified adjudicated cardiovascular events</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
    <description>Major cardiovascular adverse events: myocardial infarction, death from all causes, chronic heart failure requiring hospitalization, unstable angina requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by occurrence of prespecified adjudicated cerebrovascular events</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
    <description>Stroke or death from all causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by time to occurrence of prespecified adjudicated cerebrovascular events</measure>
    <time_frame>Up to End of Study (EOS) (Up to week 108)</time_frame>
    <description>Stroke or death from all causes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">838</enrollment>
  <condition>Anemia</condition>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <arm_group>
    <arm_group_label>roxadustat treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose adjustments are allowed during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESA (Erythropoiesis Stimulating Agent) treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment administered can be epoetin alfa or darbepoetin alfa. Dose adjustments are allowed during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roxadustat</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>roxadustat treatment</arm_group_label>
    <other_name>ASP1517</other_name>
    <other_name>FG-4592</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin alfa</intervention_name>
    <description>Subcutaneous (SC) or Intravenous (IV) Injection</description>
    <arm_group_label>ESA (Erythropoiesis Stimulating Agent) treatment</arm_group_label>
    <other_name>Eprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darbepoetin alfa</intervention_name>
    <description>Subcutaneous or Intravenous Injection</description>
    <arm_group_label>ESA (Erythropoiesis Stimulating Agent) treatment</arm_group_label>
    <other_name>Aranesp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main Inclusion:

          -  Subject is on stable hemodialysis (HD), hemodiafiltration (HDF) or peritoneal dialysis
             (PD) treatment with the same mode of dialysis for ≥4 months prior to randomization.

          -  Subject is on IV or SC epoetin or IV or SC darbepoetin alfa treatment for ≥8 weeks
             prior to randomization with stable weekly doses (during 4 weeks prior to
             randomization).

          -  Mean of the subject's three most recent Hb values, as measured by central laboratory,
             during the Screening Period.

          -  Subject's alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are ≤3 x
             upper limit of normal (ULN), and total bilirubin (TBL) is ≤1.5 x ULN.

        Exclusion Criteria:

        Main Exclusion:

          -  Subject has received a red blood cell (RBC) transfusion within 8 weeks prior to
             randomization.

          -  Subject has a known hereditary hematologic disease such as thalassemia or sickle cell
             anemia, pure red cell aplasia, or other known causes for anemia other than Chronic
             Kidney Disease (CKD).

          -  Subject has had a myocardial infarction, acute coronary syndrome, stroke, seizure, or
             a thrombotic/thrombo-embolic event (e.g., deep vein thrombosis or pulmonary embolism)
             within 12 weeks prior to randomization.

          -  Subject has had uncontrolled hypertension, in the opinion of the investigator, within
             2 weeks prior to randomization.

          -  Subject has a history of malignancy, except for the following: cancers determined to
             be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell
             skin cancers, cervical cancer in situ, or resected colonic polyps.

          -  Subject has had any prior organ transplant (that has not been explanted), or subject
             is scheduled for organ transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site BE32004</name>
      <address>
        <city>Brussels</city>
        <state>Flemish Brabant</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32001</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32019</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32002</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32012</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32017</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32003</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32013</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32011</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35925</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35931</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35915</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35909</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35919</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35920</name>
      <address>
        <city>Rousse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35938</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35924</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35906</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35921</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35907</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35916</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35918</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35903</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BG35937</name>
      <address>
        <city>Yambol</city>
        <zip>8600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38509</name>
      <address>
        <city>Zagreb</city>
        <state>Grad Zagreb</state>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38508</name>
      <address>
        <city>Cakovec</city>
        <zip>40000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38505</name>
      <address>
        <city>Karlovac</city>
        <zip>47000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38507</name>
      <address>
        <city>Osijek</city>
        <zip>31 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38506</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38504</name>
      <address>
        <city>Slavonski Brod</city>
        <zip>35000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HR38501</name>
      <address>
        <city>Zadar</city>
        <zip>23 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42008</name>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42021</name>
      <address>
        <city>Praha 6</city>
        <zip>169 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CZ42015</name>
      <address>
        <city>Rakovnik</city>
        <zip>26929</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33005</name>
      <address>
        <city>Amiens cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33010</name>
      <address>
        <city>La Tronche</city>
        <zip>38701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33055</name>
      <address>
        <city>Saint Ouen</city>
        <zip>93400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33007</name>
      <address>
        <city>Saint Priez En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site FR33056</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GE99504</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GE99508</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49056</name>
      <address>
        <city>Dormagen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41540</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49067</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49073</name>
      <address>
        <city>Cloppenburg</city>
        <zip>49661</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49008</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49054</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49020</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49065</name>
      <address>
        <city>Hamburg</city>
        <zip>23397</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49075</name>
      <address>
        <city>Heilbronn</city>
        <zip>74076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49001</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49070</name>
      <address>
        <city>Muenchen</city>
        <zip>81695</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49002</name>
      <address>
        <city>Solingen</city>
        <zip>42653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DE49071</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36033</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36007</name>
      <address>
        <city>Budapest</city>
        <zip>H 1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36036</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36031</name>
      <address>
        <city>Gyor</city>
        <zip>9002</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36026</name>
      <address>
        <city>Kaposvar</city>
        <zip>H 7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36027</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36032</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36035</name>
      <address>
        <city>Pecs</city>
        <zip>7633</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36004</name>
      <address>
        <city>Szeged</city>
        <zip>6724</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36046</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36006</name>
      <address>
        <city>Szombathely</city>
        <zip>H 9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site HU36003</name>
      <address>
        <city>Zalsaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39028</name>
      <address>
        <city>Prato</city>
        <state>Frazione Di Galciana</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39039</name>
      <address>
        <city>Cremona</city>
        <state>Lombardia</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39014</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39008</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39006</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39037</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39022</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39036</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39005</name>
      <address>
        <city>Roma</city>
        <zip>122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39035</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site IT39032</name>
      <address>
        <city>Trieste</city>
        <zip>34142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48002</name>
      <address>
        <city>Katowice</city>
        <zip>40 027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48001</name>
      <address>
        <city>Krakow</city>
        <zip>30 501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48013</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48006</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48014</name>
      <address>
        <city>Zamosc</city>
        <zip>20-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35121</name>
      <address>
        <city>Almada</city>
        <zip>2800-455</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35127</name>
      <address>
        <city>Aveiro</city>
        <zip>3800-266</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35117</name>
      <address>
        <city>Faro</city>
        <zip>8005-546</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35128</name>
      <address>
        <city>Gaeiras</city>
        <zip>2510-702</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35114</name>
      <address>
        <city>Leiria</city>
        <zip>2400-441</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35102</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PT35122</name>
      <address>
        <city>Setubal</city>
        <zip>2900-655</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40020</name>
      <address>
        <city>Odorheiu Secuiesc</city>
        <state>Harghita</state>
        <zip>535600</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40018</name>
      <address>
        <city>Bucharest</city>
        <zip>011794</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40015</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40019</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40003</name>
      <address>
        <city>Bucuresti</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RO40004</name>
      <address>
        <city>Oradea</city>
        <zip>410562</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70008</name>
      <address>
        <city>Kaluga</city>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70051</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70005</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70073</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70003</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70004</name>
      <address>
        <city>Omsk</city>
        <zip>644112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70014</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70072</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70002</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70011</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70050</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70030</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70037</name>
      <address>
        <city>Volgograd</city>
        <zip>404120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RU70001</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38102</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38105</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38120</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38104</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38117</name>
      <address>
        <city>Krusevac</city>
        <zip>37000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38101</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38116</name>
      <address>
        <city>Zrenjanin</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42102</name>
      <address>
        <city>Koshice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42119</name>
      <address>
        <city>Levice</city>
        <zip>93401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42120</name>
      <address>
        <city>Lučenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42113</name>
      <address>
        <city>Puchov</city>
        <zip>020 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site SK42116</name>
      <address>
        <city>Senica</city>
        <zip>90501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34041</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34009</name>
      <address>
        <city>El Ejido</city>
        <state>Almeria</state>
        <zip>04700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34010</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34030</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34011</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34002</name>
      <address>
        <city>Badalona-Barcelona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34008</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34006</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34039</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34017</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34037</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site ES34052</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44087</name>
      <address>
        <city>Brighton</city>
        <state>EastSussex</state>
        <zip>BN2 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44011</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44008</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44010</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44081</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44079</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site GB44001</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP1517</keyword>
  <keyword>FG-4592</keyword>
  <keyword>Anemia</keyword>
  <keyword>End Stage Renal Disease (ESRD)</keyword>
  <keyword>Erythropoetin Stimulating Agents (ESAs)</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Hematopoetic Agents</keyword>
  <keyword>HIF-PH inhibitor</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Dialysis</keyword>
  <keyword>roxadustat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

